Epidemiology & Geographic Distribution

CKDu Prevalence: - 1–5% of populations in Central America (El Salvador, Guatemala, Nicaragua, Costa Rica) - 5–10% in some rural agricultural regions - 500,000–1,000,000 estimated cases across Mesoamerica - Male predominance (10:1 male-to-female ratio) - Overwhelmingly affects agricultural workers (sugarcane cutters, cotton farmers, rice paddies)

Case Definition (KDIGO 2017): - CKD: GFR <60 mL/min/1.73m² on at least 2 occasions - Unknown etiology: Absence of diabetes, hypertension, autoimmune disease, chronic glomerulonephritis on serologies, or other established CKD cause - Early-stage at diagnosis: 67% present with eGFR 30–60 (Stage 3), only 20% present with Stage 5

Pathophysiology: Heat Stress Nephropathy

Proposed Mechanism: 1. Occupational heat exposure: Chronic dehydration from repeated heat stress (sugarcane work in tropical climate) 2. Repeated volume depletion: Workers exposed to 40°C+ ambient temperature without adequate hydration 3. Transient hyperfiltration: Periods of intense activity followed by severe dehydration cause glomerular stress 4. Tubular injury: Recurrent episodes of acute tubular necrosis (ATN) from dehydration 5. Uric acid crystallization: Dehydration and volume contraction promote uric acid precipitation in distal tubules 6. Inflammatory cascade: Repeated injury → local inflammation → fibrosis accumulation

Evidence Supporting Heat-Stress Etiology: - Time-trend data: Incidence increased coincident with intensification of sugarcane harvesting practices (mechanization, speed pressure) - Seasonal variation: CKD progression faster during dry season (peak heat stress) - Occupational clustering: 20–30-fold higher prevalence in sugarcane cutters vs. non-agricultural workers - Cross-sectional data: Objective heat stress metrics correlate with kidney function decline - Animal models: Repeated heat-induced dehydration causes progressive tubular injury and fibrosis in rats

Clinical Features of CKDu/Mesoamerican Nephropathy

Presentation: - Asymptomatic CKD: Most cases discovered on screening (elevated creatinine) rather than symptoms - Age at diagnosis: 20–50 years (much younger than typical CKD from diabetes/hypertension) - Minimal proteinuria: <1 g/day (urine protein often <300 mg/day) — atypical for CKD stage - Preserved hematuria response: Most have no or microscopic hematuria - Normal blood pressure initially: Many normotensive despite Stage 3–4 CKD

Laboratory Features: - Elevated creatinine: Often 1.5–3.5 mg/dL at discovery - Elevated uric acid: Hyperuricemia common (may reflect tubular dysfunction) - Normal urinalysis: Minimal proteinuria, no dysmorphic RBC, no casts - Absence of serologic markers: Negative ANA, ANCA, anti-GBM, normal complement - Normal glucose/normal HbA1c: No diabetes in classic CKDu cases

Renal Imaging: - Ultrasound: Small, echogenic kidneys (size often <9 cm); loss of corticomedullary differentiation - CT: Chronic tubulointerstitial changes; cortical thinning; minimal or absent glomerular sclerosis

Kidney Biopsy Findings in CKDu

Light Microscopy (When available; biopsy not routinely done in endemic areas): - Tubulointerstitial injury predominates: Tubular atrophy, interstitial fibrosis (TIF) - Glomerular changes minimal: Glomeruli often remarkably spared or show global sclerosis without proliferation - Tubular changes: Atrophic tubules, loss of brush border, epithelial flattening - Chronic inflammation: Interstitial lymphocytic infiltration - Vascular changes: Arteriolar hyalinosis variable

IF: Negative or nonspecific IgM in sclerotic glomeruli

EM: Tubular basement membrane changes; podocyte foot process fusion; glomerular changes less prominent

Key Point: The striking feature is glomeruli-sparing pattern — glomeruli are relatively preserved while tubulointerstitium shows severe injury, opposite of typical immune-mediated GN.

Differential Diagnosis of CKDu

Clinical Management & Prevention

For Patients with Established CKDu: 1. Slow progression: ACE inhibitor or ARB to reduce proteinuria (even modest amount) 2. Uric acid management: Allopurinol (no strong data but theoretically beneficial); maintain uric acid <6 mg/dL 3. Blood pressure control: Target <120/80 mm Hg 4. Avoid nephrotoxins: NSAIDs strictly contraindicated 5. Dialysis access: Early vascular access planning for Stage 4 (many will reach Stage 5 by age 40–50)

Prevention Strategies (Public Health): 1. Occupational health interventions: - Mandatory hydration breaks (at least 1 L per 1–2 hours of work in high heat) - Electrolyte replacement (sodium) in addition to water - Earlier shifts (reduced peak heat exposure) - Cool-rest areas - Speed limits on piece-rate work (reduce pressure to work faster despite heat stress)

2. Monitoring & screening:
   • Annual creatinine/eGFR screening in high-risk agricultural populations
   • Early detection allows counseling about CKDu risk and occupational alternatives
3. Health system strengthening:
   • Training of primary care providers in CKDu recognition
   • Accessible dialysis capacity in endemic regions (currently severe shortage)
4. Research & surveillance:
   • Continued mechanistic studies to confirm heat-stress etiology
   • Environmental monitoring of occupational heat stress
   • Registry studies to track epidemiology and outcomes

Epidemiology & Parasitology

Prevalence: - 250–300 million infected worldwide (Africa, Middle East, South America) - Two main species causing kidney disease: - Schistosoma haematobium (hematuria, urinary schistosomiasis) — Africa, Middle East - Schistosoma mansoni (intestinal schistosomiasis) — Africa, South America

Transmission: - Larval cercariae in freshwater (rivers, lakes, ponds) - Penetrate skin during contact with water - Develop into adult worms in venous plexuses

Pathophysiology of Schistosomiasis-Related Kidney Disease

Mechanism: 1. Egg deposition: Schistosome eggs lodge in various organs 2. Immune response: Granulomatous inflammation around eggs (Th1 and Th2 mediated) 3. Circulating immune complexes: Soluble egg antigens form IC 4. Glomerular deposition: IC deposit in glomerular basement membrane 5. Complement activation: Classical pathway activation → C3, C5a → inflammation 6. Progressive glomerular injury: Proliferation, crescents, scarring

Clinical Features & Types

Schistosomiasis Haematobium (Urinary): - Presentation: Chronic hematuria, dysuria - Chronic sequelae: Fibrosis of bladder/ureter, chronic cystitis, squamous cell cancer - Kidney involvement: Usually ureteral/bladder pathology predominates over glomerular disease - Biopsy findings (when GN occurs): Membranoproliferative or proliferative GN, sometimes crescentic

Schistosomiasis Mansoni (Intestinal): - Presentation: Diarrhea, abdominal pain, hepatosplenomegaly - Chronic sequelae: Intestinal fibrosis, portal hypertension, liver cirrhosis - Kidney involvement: More frequent glomerulonephritis (immune complex-mediated) - Proteinuria: Nephrotic range possible (10–15 g/day)

Glomerulonephritis Patterns in Schistosomiasis

Light Microscopy: - Membranoproliferative GN (most common): Tram-track capillaries, mesangial proliferation - Proliferative GN: Endocapillary or mesangial proliferation - Membranous nephropathy: Less common; mimics primary MN - Crescentic GN: Rare; indicates severe disease - Mesangial expansion: With electron-dense deposits

Immunofluorescence: - Granular IgG + IgM + C3: Consistent with immune complex disease - C1q often present (indicates classical pathway activation) - Pattern similar to post-infectious GN or lupus

Electron Microscopy: - Immune-dense deposits: Variable size and location (subendothelial, intramembranous, mesangial) - No amyloid fibrils - Foot process effacement variable depending on proteinuria degree

Management & Prognosis

Anthelmintic Therapy: - Praziquantel: 40–60 mg/kg single dose (highly effective for adult worm elimination) - Goal: Reduce worm burden and egg production - Timing: Early treatment in acute phase prevents chronic progression - Limitation: Chronic glomerular disease often irreversible once established

Immunosuppression: - Limited role: Standard GN therapy (corticosteroids, immunosuppressants) not routinely used - Rationale: Chronic schistosomiasis is persistent infection; immune suppression risky - Exception: If crescentic GN with rapid AKI, pulse corticosteroids may be considered

Supportive Care: - Proteinuria reduction: ACE inhibitor/ARB to slow GFR decline - Blood pressure control: Target <120/80 - Dialysis: If ESRD develops (limited availability in endemic regions)

Prognosis: - If treatment early: Often arrests progression; can improve proteinuria - If treatment delayed: Progressive to CKD/ESRD (50–70% progression rate in untreated chronic disease) - Mortality: Often dies from hepatic cirrhosis or malignancy before ESRD if M. mansoni

Epidemiology

• 400+ million malaria cases annually
• Acute kidney injury and glomerulonephritis can occur in severe malaria
• Most common with Plasmodium falciparum (most severe species)

Pathophysiology

Two Main Mechanisms:

1. Acute Kidney Injury (AKI) from severe malaria parasitemia:
   • Direct tubular toxicity from hemoglobinuria (massive hemolysis)
   • Severe metabolic acidosis → myoglobinuria + hemoglobinuria
   • Hypovolemia from diarrhea/fever
   • DIC (disseminated intravascular coagulation) in severe malaria
   • Complications: Acute tubular necrosis, acute cortical necrosis (rare)
2. Glomerulonephritis from immune complex deposition:
   • Circulating immune complexes (parasitic antigens + antibodies)
   • Persistent parasitemia in chronic malaria (endemic areas) → chronic IC GN
   • Complement activation → proliferative GN

Clinical Features

Acute Malaria with AKI: - Presentation: Fever, chills, headache, muscle aches; rapid rise in creatinine - Renal manifestations: Oliguria (urine output <400 mL/day), rapidly rising creatinine - Urine findings: Pigmenturia (tea-colored from myoglobin/hemoglobin), proteinuria, muddy brown casts - Hyperkalemia: From hemolysis and AKI - Metabolic acidosis: Often profound

Chronic Malaria-Associated GN: - Proteinuria: Nephrotic range in some cases - Hematuria: May or may not present - Progressive CKD: Over months to years in endemic areas

Biopsy Findings

LM: Membranoproliferative or proliferative GN; sometimes can see parasitic debris

IF: Granular IgG, IgM, C3 (immune complex pattern)

EM: Electron-dense deposits (variable location)

Management

Acute Malaria-Associated AKI: 1. Antimalarial therapy: Artemisinin-based combination therapy (ACT) — urgent 2. Volume assessment and aggressive supportive care: - IV hydration if hypovolemic; careful diuretics if fluid overload 3. Electrolyte management: Monitor K+, correct hyperkalemia (insulin-dextrose, calcium gluconate, dialysis) 4. Dialysis: Indicated if oliguric AKI unresponsive to conservative management

Chronic Malaria-Associated GN: - Antimalarial treatment (difficult in endemic areas with drug resistance) - Proteinuria reduction (ACE inhibitor/ARB) - Blood pressure control

Prognosis: - Acute AKI: High mortality if severe (20–50% mortality in falciparum malaria with renal failure) - Recovery: Many recover renal function if survive acute episode - Chronic GN: Slow progressive decline to CKD

Balkan Endemic Nephropathy (BEN)

Geography & Epidemiology: - Endemic in Balkan Peninsula (Serbia, Bosnia, Bulgaria, Croatia, Romania) - Affects up to 10% of rural populations in some villages - Associated with living along Danube River tributaries

Etiology (Likely): - Aristolochic acid exposure: From plants (Aristolochia species) contaminating grain crops - Soil-based heavy metals (possibly cadmium) - Genetic predisposition possible

Clinical Features: - Painless hematuria (often first sign; may intermittent) - Progressive proteinuria: Usually <1 g/day (tubular proteinuria) - Slowly progressive CKD: To ESRD over 20–30 years - No systemic features: Normotensive in early disease - Age: Presents in 40s–60s (chronic exposure) - Anemia: Often severe (degree out of proportion to GFR) - Urothelial cancer risk: 100–200-fold increased risk of transitional cell carcinoma of ureter/bladder

Biopsy Findings (Rare): - Tubulointerstitial changes predominate: Chronic TIF, glomeruli relatively spared - LM: Severe interstitial fibrosis, tubular atrophy; glomeruli appear relatively preserved - IF: Usually negative or minimal - EM: Tubular basement membrane abnormalities

Prevention/Management: - Avoid aristolochic acid exposure: Stop use of traditional herbal remedies containing Aristolochia - Cancer surveillance: Annual urine cytology, abdominal imaging for urothelial malignancy - Supportive care: ACE inhibitor/ARB, blood pressure control, dialysis for ESRD

Aristolochic Acid Nephropathy (AAN)

Epidemiology: - Caused by chronic exposure to aristolochic acid (AA) - Associated with traditional Chinese herbal remedies (weight-loss pills, traditional medicine) - Cases reported in Europe, Asia, North America (from contaminated supplements)

Mechanism: - DNA adducts: AA covalently binds DNA → mutations in tumor suppressor genes (TP53) - Cumulative exposure effect: Dose-dependent risk - Species variation: Human mutation signature distinct (can identify AA-exposed kidney cancers by genetics)

Clinical Features: - Asymptomatic CKD: Often detected on routine urinalysis or creatinine screening - Minimal proteinuria: <1 g/day typical - Hematuria: May be present - Rapid progression: Can progress to ESRD within 5–10 years of recognition - Small kidneys: On imaging - Cancer risk: 5–10-fold increased urothelial cancer risk

Biopsy Findings: - Similar to BEN: tubulointerstitial predominance, glomeruli-sparing pattern - Severe chronic interstitial fibrosis and tubular atrophy

Management: - Cessation of exposure: Must identify and stop herbal remedy use - Cancer surveillance: Annual urine cytology, abdominal imaging - CKD progression monitoring: ACE inhibitor/ARB - Dialysis/transplant: As needed for ESRD

Tuberculosis (TB) and the Kidney

Renal TB Epidemiology: - 10–20% of patients with pulmonary TB develop extrapulmonary TB - Renal TB occurs in ~5% of TB patients - Often diagnosed late (years after primary TB infection)

Pathophysiology: - Hematogenous seeding: During primary TB infection - Latency: Bacilli lie dormant in renal tissue - Reactivation: Years later, local renal inflammation develops - Progressive fibrosis: Leads to loss of renal function

Clinical Features: - Asymptomatic bacteriuria: Sterile pyuria (WBC in urine without bacterial growth on routine culture) - Hematuria: Often gross - Flank pain: Possible if localized infection - Dysuria: If bladder involvement - Constitutional symptoms: Fever, night sweats, weight loss (may be absent initially)

Radiologic Findings: - “Moth-eaten” calyceal destruction: Classic finding - Strictures of ureter: Leading to hydronephrosis - Cavitary lesions: In renal parenchyma - Bladder contraction: From fibrosis (late finding)

Diagnosis: - Urine AFB culture: Gold standard (requires 24-hour or multiple urine collections; positive in 50% of renal TB) - Urine PCR for TB: Increasingly used - Imaging: Characteristic CT findings - Biopsy: Rarely needed (shows granulomas)

Management: - Anti-TB therapy: Standard 6-month regimen (RIPE: Rifampin, Isoniazid, Pyrazinamide, Ethambutol) - Extended therapy: May need 9 months for renal TB (slower penetration) - Surgical intervention: Nephrectomy if end-stage renal TB or recurrent complications - Ureteral stenting: For strictures causing obstruction

Renal Outcomes: - Early treatment: Often arrest disease; prevent ESRD - Late diagnosis: May progress to chronic fibrosis and CKD even after cure - Proteinuria: Usually <1 g/day

Fungal Infections and Candiduria

Candida Nephritis: - Risk factors: Immunosuppression (HIV, chemotherapy), indwelling urinary catheters, diabetes - Presentation: Hematuria, pyuria, positive urine culture (Candida species) - Renal manifestations: Usually asymptomatic; can progress to renal abscess or fungal ball - Biopsy (rare): Shows granulomatous inflammation with fungal organisms

Other Endemic Fungi: - Histoplasmosis: Can cause granulomatous kidney disease - Coccidioidomycosis: Rarely causes GN - Cryptococcosis: In HIV patients; can cause granulomatous interstitial nephritis

Epidemiology of ESRD Burden

Global CKD Prevalence: - 8–16% of global population has CKD Stage 1–5 - Highest burden in low-income and middle-income countries (LMIC) - 1–2 million deaths annually attributed to kidney disease

Dialysis Access: - Developed countries: ~90% of ESRD patients on dialysis - Developing countries: 10–30% of ESRD patients can access dialysis - Lowest income countries: <5% access to dialysis

Transplant Access: - High-income countries: 50% of ESRD patients have transplants - Low-income countries: <5% of ESRD patients have transplants - Medical loss-to-follow-up: 50–70% of CKD Stage 4 patients lost before reaching ESRD in LMIC

Barriers to Care

Structural Barriers: 1. Infrastructure: Lack of dialysis centers and trained personnel 2. Technology: Inadequate RO (reverse osmosis) capacity, water supply unreliable 3. Medication availability: Limited access to erythropoietin, phosphate binders 4. Financial: Dialysis unaffordable; private out-of-pocket spending dominates

Healthcare System Barriers: - Provider shortage: Few nephrologists per capita in LMIC - Screening/early detection: Lack of CKD screening programs - Referral pathways: Absent or inefficient

Patient-Level Barriers: - Poverty: Cannot afford treatment; prioritize food over dialysis - Education: Low health literacy; late presentation - Geography: Rural populations far from dialysis centers - Gender: Women less likely to access transplant due to social norms

Impact of Disparities

Clinical Outcomes: - Mortality: Dialysis patients in LMIC have 5-year mortality >50% (vs. 35% in developed countries) - Infection rates: Higher due to inadequate water quality, dialysis center staffing - Vascular access: Longer time to functional fistula, higher catheter use (infection risk)

Transplant Outcomes: - Minimal-group transplants: Widespread due to limited deceased donor organs - Immunosuppression adherence: Low due to cost; higher rejection rates - Recurrent disease: Inadequate monitoring post-transplant

Solutions & Advocacy (WHO Kidney Disease Report)

Policy Level: 1. Include ESRD in WHO Essential Medicines List: Improve access to renal medications 2. Strengthen primary care: Hypertension/diabetes screening to prevent CKD progression 3. Water safety: Ensure potable water for dialysis (often lacking) 4. Workforce training: Support nephrology training in LMIC

Healthcare System: - Telemedicine: Remote monitoring for dialysis patients - Task-sharing: Train nurse practitioners and physician assistants for dialysis management - Peritoneal dialysis expansion: More accessible than hemodialysis in some settings (home-based)

Community-Level: - Screening programs: Identify early CKD in high-risk populations - Public awareness: Education about hypertension, diabetes, kidney disease prevention - Medication access: Advocacy for affordable BP meds, diabetes medications